Entera Bio Ltd. (ENTX)
- Previous Close
2.2200 - Open
2.2000 - Bid 1.9800 x 100
- Ask 2.1500 x 100
- Day's Range
2.0100 - 2.2575 - 52 Week Range
0.5200 - 3.3500 - Volume
163,338 - Avg. Volume
230,364 - Market Cap (intraday)
73.446M - Beta (5Y Monthly) 1.71
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3100 - Earnings Date May 3, 2024 - May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
www.enterabio.comRecent News: ENTX
Performance Overview: ENTX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENTX
Valuation Measures
Market Cap
73.45M
Enterprise Value
62.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
7.07
Enterprise Value/Revenue
3.21k
Enterprise Value/EBITDA
-7.11
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.65%
Return on Equity (ttm)
-80.30%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.89M
Diluted EPS (ttm)
-0.3100
Balance Sheet and Cash Flow
Total Cash (mrq)
11.02M
Total Debt/Equity (mrq)
3.76%
Levered Free Cash Flow (ttm)
-3.82M
Research Analysis: ENTX
Company Insights: ENTX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: ENTX
Daily – Vickers Top Buyers & Sellers for 01/12/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 04/13/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 04/12/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 04/11/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.